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Activated protein C protects 
against diabetic nephropathy
Renal abnormalities in early diabetic nephropathy include 
increases in glomerular ﬁltration rate and albuminuria, which 
are due, at least in part, to glomerular capillary damage. It is 
well documented that podocyte integrity, an important determi-
nant of the permselective properties of the glomerular ﬁltration 
barrier, is impaired in subjects with diabetic nephropathy. The 
glomerular endothelium also contributes to the permselective 
properties of the glomerular barrier, but it is unknown whether 
endothelial dysfunction is causally related to impairment of the 
glomerular ﬁltration barrier in diabetic nephropathy.
Protein C is a vitamin K-dependent plasma proenzyme. Its 
partial or complete genetic deﬁciencies cause venous thrombosis 
or neonatal purpura fulminans, respectively. It has long been 
known that activated protein C (APC) inactivates factors Va 
and VIIIa to downregulate thrombin generation. More recent 
work has shown that APC has direct cytoprotective eﬀects that 
involve gene expression proﬁle alterations, anti-inﬂammatory 
and antiapoptotic activities, and endothelial barrier stabilization. 
In unperturbed endothelial cells, activation of protein C that 
is dependent on thrombomodulin (encoded by Thbd) inhib-
its coagulation, inﬂammation, and apoptosis. Function of the 
endothelial thrombomodulin–protein C system is impaired 
in diabetic individuals, as shown by increased levels of soluble 
thrombomodulin, thought to reﬂect loss of thrombomodulin 
from the endothelium, and decreased levels of APC. Thus, per-
turbation of the thrombomodulin–protein C system resulting in 
reduced levels of APC is a potential mechanism of glomerular 
capillary dysfunction in diabetes.
In a recent manuscript, Isermann et al. examined the role 
of APC in endothelial and glomerular capillary dysfunction. 
They found that persistent hyperglycemia reduced thrombo-
modulin expression and APC formation in wild-type mice in 
vivo (Figure). To determine whether the loss of thrombomodu-
lin-dependent protein C activation and diabetic nephropathy 
are causally linked, they tested genetically engineered mice in 
which APC formation was either impaired or enhanced. Diabetic 
nephropathy was worse in mice with genetically imposed losses 
of protein C activation; conversely, mice with increased APC for-
mation were protected from diabetic nephropathy. The authors 
discovered that this protection was not due to diﬀerent throm-
bomodulin expression levels, and that APC was renoprotective 
independently of blood clotting. APC prevented endothelial-
cell (and podocyte) apoptosis by modulating the mitochondrial 
apoptosis pathway via the protease-activated receptor PAR-1 and 
the endothelial protein C receptor EPCR in glucose-stressed cells. 
These elegant experiments establish a new pathway in which 
hyperglycemia impairs endothelial thrombomodulin-dependent 
APC formation and causes glomerular apoptosis and diabetic 
nephropathy. Conversely, maintaining high APC levels during 
long-term diabetes protects against diabetic nephropathy. (Nat 
Med 2007; 13: 1349–1358; doi:10.1038/nm1667)
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Benefits of frequent nocturnal 
versus conventional hemodialysis 
on left ventricular mass and 
quality of life
Prior cohort studies demonstrate improvements in multiple 
measures, including blood pressure control, phosphorus control, 
and quality of life, among patients moving toward more frequent 
dialysis (either daily or nocturnal). Although results have been 
compelling, the lack of control groups and potential Hawthorne 
eﬀect arguably diminish the strength of these conclusions.
Culleton et al. reported the results of a trial of 52 preva-
lent hemodialysis patients randomized to frequent nocturnal 
hemodialysis versus conventional dialysis. Frequent nocturnal 
dialysis improved mean left ventricular mass as compared with 
Glomeruli from a nondiabetic (a) and a diabetic (b) wild-type (WT) 
mouse. Thrombomodulin (TM) is strongly expressed in glomerular 
capillaries of the nondiabetic (a, arrow) but not of the diabetic (b, 
arrow) mouse.
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Immunostaining for CD3 and immunofluorescence for the T-cell receptor 
(TcR) showed that angiotensin II (Ang II) markedly increased the number 
of T cells in the aortic adventitia, particularly in the periadventitial fat.
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interventions prevents hypertension in several experimental 
models. Infusion of alloactivated T cells for treatment of cancer 
increases blood pressure in humans. Activation of both humoral 
and cellular immunity occurs in women with preeclampsia. 
Conversely, suppression of the adaptive immune system can 
inhibit hypertension in experimental animals and humans. All 
these studies suggest that adaptive immunity contributes to 
hypertension via yet undeﬁned mechanisms.
In a recent study, Guzik et al. addressed this question and 
found that hypertension due to angiotensin II infusion was 
blunted in mice lacking T and B cells (RAG-1–/– mice). They 
also found that the mice did not develop abnormalities of vas-
cular function. Adoptive transfer of T, but not B, cells restored 
the hypertension and the vascular abnormalities. When the 
authors transferred T cells lacking the angiotensin type I 
receptor or a functional NADPH oxidase, the angiotensin 
II-dependent hypertension was blunted and aortic O2
•– pro-
duction decreased. Additionally, angiotensin II increased 
T-cell markers of activation and tissue homing in wild-type, 
but not in NADPH oxidase-deﬁcient, mice. Angiotensin II 
also increased T cells in the perivascular adipose tissue and 
the adventitia (Figure). These cells expressed high levels of CC 
chemokine receptor 5 and were commonly double negative 
(CD3+CD4–CD8–). This inﬁltration was associated with an 
increase in intercellular adhesion molecule-1 and RANTES in 
the aorta. Hypertension also increased T-lymphocyte produc-
tion of tumor necrosis factor-α (TNF-α). Further, treatment 
with the TNF-α antagonist etanercept prevented the hyperten-
sion and increase in vascular O2
•– caused by angiotensin II. In 
addition, RAG-1–/– mice had blunted hypertensive response 
to the administration of deoxycorticosterone acetate plus salt, 
indicating that their lymphocytes play a role in other causes 
of hypertension. These studies identify a previously undeﬁned 
role for T cells and inﬂammation in the pathogenesis of hyper-
tension. T cells might represent a novel therapeutic target for 
the treatment of high blood pressure. (J Exp Med 2007; 204: 
2449–2460; doi:10.1084/jem.20070657)
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conventional dialysis (diﬀerence 15.3 g, P = 0.04). Frequent 
dialysis also improved mineral metabolism (a decrement in 
serum phosphate of 1.5 mg/dl between groups (P < 0.01) with 
a concurrent decrease in elemental calcium use as a binder in 
the frequent-dialysis group (P < 0.001). Although changes in 
overall quality of life were not diﬀerent between groups, those 
subjects in the frequent-dialysis group experienced improve-
ments in selected kidney-speciﬁc domains.
The results of this trial clearly provide an optimistic outlook 
on the improved delivery of renal replacement therapies, which 
could improve cardiovascular outcomes or survival in patients 
with end-stage renal disease. In addition to providing valuable 
information for the conﬁrmation of prior observational stud-
ies and the estimation of treatment eﬀect to perform or con-
ﬁrm power calculations for larger studies, this study provides a 
practical message. Although larger trials likely will conﬁrm the 
beneﬁcial eﬀect on intermediate and/or hard clinical outcomes, 
widespread use of this modality needs to be considered. Only 
one subject in the frequent-dialysis arm discontinued participa-
tion because of technical problems with home dialysis, indicating 
that this modality was successfully performed. However, in the 
enrollment of this trial, only about 10% of available patients were 
interested in nocturnal dialysis. Hopefully, the Frequent Hemo-
dialysis Network trials, sponsored by the National Institutes of 
Health, will demonstrate additional beneﬁts. Our challenge as a 
renal community is to determine how to implement these thera-
pies in countries such as the United States, where home therapies 
such as peritoneal dialysis are not given to a large proportion of 
patients. (JAMA 2007; 298: 1291–1299)
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T cells are involved in angiotensin 
II-induced hypertension and 
vascular dysfunction
Angiotensin II is a potent vasoconstrictor and salt-retaining 
hormone whose excess can cause hypertension. Reactive oxy-
gen species (ROS) produced by the Nox-based nicotinamide 
adenosine dinucleotide phosphate (NADPH) oxidases have 
recently been implicated in several models of experimental 
hypertension. These multisubunit enzymes are similar to the 
neutrophil oxidases that are present in vascular cells, kidney, 
and central nervous system. Angiotensin II can activate these 
enzymes; the superoxide (O2
•–) that is produced can react 
with the endogenous vasodilator nitric oxide (NO), thereby 
promoting vasoconstriction. This could increase systemic vas-
cular resistance and elevate blood pressure. It has also been 
proposed that O2
•– and related ROS can increase renal sodium 
reabsorption, which could also contribute to hypertension. 
T lymphocytes contain a functional NADPH oxidase and 
an angiotensin type I receptor. Angiotensin II stimulates 
T-cell proliferation and is known to stimulate ROS production 
via NADPH oxidase in several cells. Moreover, perturbation 
of immune function by thymectomy or by pharmacological 
